[A nomogram prediction model for individualized prediction of the risk of covert (minimal) hepatic encephalopathy occurrence in patients with liver cirrhosis].

X Q Li, Y Li, Y Q Ni, W Cao, T T Yin, R Lu
{"title":"[A nomogram prediction model for individualized prediction of the risk of covert (minimal) hepatic encephalopathy occurrence in patients with liver cirrhosis].","authors":"X Q Li, Y Li, Y Q Ni, W Cao, T T Yin, R Lu","doi":"10.3760/cma.j.cn501113-20230806-00035","DOIUrl":null,"url":null,"abstract":"<p><p><b>Objective:</b> To construct an individualized nomogram prediction model for predicting the risk of the occurrence of covert hepatic encephalopathy (CHE) in patients with liver cirrhosis. <b>Methods:</b> 325 cases of liver cirrhosis admitted from January 2020 to December 2022 were selected as the study subjects. Patients were divided into training (<i>n</i>=213) and validation (<i>n</i>=112) sets using a cluster randomization method. The risk factors for CHE occurrence in patients with cirrhosis in the training set were analyzed by univariate and multivariate logistic regression. A prediction model related to the nomogram was established. <b>Results:</b> Independent risk factors for the occurrence of CHE in patients with cirrhosis were a history of hepatic encephalopathy, co-infection, gastrointestinal bleeding, severe ascites, prothrombin time ≥16 seconds, high total bilirubin, and high blood ammonia levels (<i>P</i><0.05). Nomogram model validation results: The model had a net benefit for the training and validation sets, with C-indices of 0.830 (95%<i>CI</i>: 0.802-0.858) and 0.807 (95%<i>CI</i>: 0.877-0.837), respectively, within the range of 0-96%. The calibration curves of both sets were evenly close to the ideal curves. The AUCs for the ROC curves in both sets were 0.827 (95%<i>CI</i>: 0.796-0.858) and 0.811 (95%<i>CI</i>: 0.787-0.836), respectively. <b>Conclusion:</b> Patients with cirrhosis have many risk factors for CHE occurrence. The nomogram model constructed based on these risk factors possesses a good predictive value for assessing CHE occurrence in cirrhotic patients.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 9","pages":"828-834"},"PeriodicalIF":0.0000,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华肝脏病杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/cma.j.cn501113-20230806-00035","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: To construct an individualized nomogram prediction model for predicting the risk of the occurrence of covert hepatic encephalopathy (CHE) in patients with liver cirrhosis. Methods: 325 cases of liver cirrhosis admitted from January 2020 to December 2022 were selected as the study subjects. Patients were divided into training (n=213) and validation (n=112) sets using a cluster randomization method. The risk factors for CHE occurrence in patients with cirrhosis in the training set were analyzed by univariate and multivariate logistic regression. A prediction model related to the nomogram was established. Results: Independent risk factors for the occurrence of CHE in patients with cirrhosis were a history of hepatic encephalopathy, co-infection, gastrointestinal bleeding, severe ascites, prothrombin time ≥16 seconds, high total bilirubin, and high blood ammonia levels (P<0.05). Nomogram model validation results: The model had a net benefit for the training and validation sets, with C-indices of 0.830 (95%CI: 0.802-0.858) and 0.807 (95%CI: 0.877-0.837), respectively, within the range of 0-96%. The calibration curves of both sets were evenly close to the ideal curves. The AUCs for the ROC curves in both sets were 0.827 (95%CI: 0.796-0.858) and 0.811 (95%CI: 0.787-0.836), respectively. Conclusion: Patients with cirrhosis have many risk factors for CHE occurrence. The nomogram model constructed based on these risk factors possesses a good predictive value for assessing CHE occurrence in cirrhotic patients.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[用于个体化预测肝硬化患者隐匿性(轻微)肝性脑病发生风险的提名图预测模型]。
目的构建预测肝硬化患者隐匿性肝性脑病(CHE)发生风险的个体化提名图预测模型。方法:选取 2020 年 1 月至 2022 年 12 月期间收治的 325 例肝硬化患者作为研究对象。采用聚类随机法将患者分为训练集(n=213)和验证集(n=112)。通过单变量和多变量逻辑回归分析了训练集中肝硬化患者发生CHE的危险因素。建立了与提名图相关的预测模型。结果肝硬化患者发生 CHE 的独立危险因素分别是肝性脑病史、合并感染、消化道出血、严重腹水、凝血酶原时间≥16 秒、总胆红素高、血氨水平高(PCI:0.802-0.858)和 0.807(95%CI:0.877-0.837),范围在 0-96% 之间。两组校准曲线均接近理想曲线。两组 ROC 曲线的 AUC 分别为 0.827(95%CI:0.796-0.858)和 0.811(95%CI:0.787-0.836)。结论肝硬化患者有许多发生 CHE 的危险因素。根据这些风险因素构建的提名图模型对评估肝硬化患者的 CHE 发生率具有良好的预测价值。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
中华肝脏病杂志
中华肝脏病杂志 Medicine-Medicine (all)
CiteScore
1.20
自引率
0.00%
发文量
7574
期刊介绍:
期刊最新文献
[The Research and Application Progress of Heterologous Liver Transplantation]. [The nomogram model and its value study of Gd-EOB-DTPA enhanced MRI for preoperative diagnosis of proliferative hepatocellular carcinoma]. [Excerpt from the 2023 European Association for the Study of the Liver practice guidelines: prevention, diagnosis, and treatment of intrahepatic cholangiocarcinoma]. [Rifaximin curative effect and mechanism on monocrotaline-induced hepatic sinusoidal obstruction syndrome in mice]. [A case of Wilson's disease misdiagnosed as autoimmune hepatitis and literature review].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1